Financial reports
ARS
2023 FY
Annual report to shareholders
2 Apr 24
10-K/A
2023 FY
Annual report (amended)
20 Mar 24
10-K
2023 FY
Annual report
12 Mar 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
3 Apr 23
10-K
2022 FY
Annual report
7 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
Current reports
8-K
Departure of Directors or Certain Officers
10 Apr 24
8-K
Other Events
20 Mar 24
8-K
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
12 Mar 24
8-K
Departure of Directors or Certain Officers
6 Feb 24
8-K
Regulation FD Disclosure
5 Feb 24
8-K/A
Financial Statements and Exhibits
1 Feb 24
8-K
Corbus Pharmaceuticals Announces Proposed Public Offering
1 Feb 24
8-K
Other Events
31 Jan 24
8-K
Other Events
29 Jan 24
8-K
Regulation FD Disclosure
26 Jan 24
Registration and prospectus
424B3
Prospectus supplement
20 Mar 24
S-3
Shelf registration
13 Mar 24
424B5
Prospectus supplement for primary offering
1 Feb 24
S-3MEF
Registration of additional securities for an S-3
31 Jan 24
424B5
Prospectus supplement for primary offering
31 Jan 24
424B3
Prospectus supplement
29 Jan 24
424B3
Prospectus supplement
13 Jun 23
S-3/A
Shelf registration (amended)
12 Jun 23
S-3
Shelf registration
31 May 23
S-8
Registration of securities for employees
10 Mar 23
Proxies
DEFA14A
Additional proxy soliciting materials
10 Apr 24
DEFA14A
Additional proxy soliciting materials
2 Apr 24
DEF 14A
Definitive proxy
2 Apr 24
PRE 14A
Preliminary proxy
22 Mar 24
DEF 14A
Definitive proxy
3 Apr 23
DEFA14A
Additional proxy soliciting materials
3 Apr 23
DEF 14A
Definitive proxy
14 Nov 22
PRE 14A
Preliminary proxy
4 Nov 22
DEFA14A
Additional proxy soliciting materials
1 Apr 22
DEF 14A
Definitive proxy
1 Apr 22
Other
EFFECT
Notice of effectiveness
21 Mar 24
EFFECT
Notice of effectiveness
14 Jun 23
CORRESP
Correspondence with SEC
7 Jun 23
UPLOAD
Letter from SEC
7 Jun 23
EFFECT
Notice of effectiveness
4 May 20
CORRESP
Correspondence with SEC
30 Apr 20
CORRESP
Correspondence with SEC
24 Apr 20
UPLOAD
Letter from SEC
13 Apr 20
UPLOAD
Letter from SEC
15 Jul 19
CORRESP
Correspondence with SEC
25 Jun 19
Ownership
4
Sean F. Moran
11 Apr 24
SC 13G/A
Cormorant Asset Management, LP
18 Mar 24
4
Bihua Chen
11 Mar 24
4
Dominic Smethurst
29 Feb 24
3
Dominic Smethurst
29 Feb 24
SC 13G
MILLENNIUM MANAGEMENT LLC
28 Feb 24
SC 13G/A
K2 HealthVentures Equity Trust LLC
14 Feb 24
SC 13G
K2 HealthVentures Equity Trust LLC
14 Feb 24
SC 13G
Paradigm Biocapital Advisors LP
14 Feb 24
4
Sean F. Moran
14 Feb 24